CONNECT WITH US
HealthTech

HealthTech

Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests

Medical Xpress logo

Published on

Add as a preferred source on Google
Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. Kidney graft function stabilized after the first month of treatment and remained higher in tegoprubart-treated patients than in tacrolimus-treated patients at each reported time point, with a statistically significant kidney function benefit at 18 months. A recent analysis of BESTOW data found that tegoprubart also caused greater improvements in patient-reported health-related quality of life compared with tacrolimus in study participants. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.

Of 127 treated patients, 107 (51 taking tegoprubart and 56 taking tacrolimus) completed study treatment to week 52. Health-related quality of life improvements from baseline were observed at week 52 across all five subscales with tegoprubart, and four of five subscales with tacrolimus. Improvements were greater with tegoprubart than tacrolimus on a mental component summary, and patients on tegoprubart also had a numerically greater reduction in total symptom score from baseline.

"Treatment today with tacrolimus helps prevent organ rejection but at a high cost to patients, with side effects such as kidney toxicity, hypertension, diabetes, tremors and brain fog. , of the University of Minnesota Medical School.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.